Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience Reports Increased Revenue, Losses for Year 2003

NEW YORK, March 5 (GenomeWeb News) - Tm Bioscience reported increased revenue as well as increased net losses for the year 2003 in its year-end earnings report, released yesterday.

 

Total revenues in the year 2003 were $1.2 million, compared with $25,500 in 2002.

 

R&D expenses for the company rose to $3 million for the full-year 2003, compared with $2.5 million in 2002.

 

Net losses for the year were $7.8 million, or $.06 per share, in 2003. This compares with losses of $5.5 million, or $.05 per share, in 2002.

 

As of Dec. 31, 2003, Tm Bioscience had $2.7 million in cash and cash equivalents.

 

Tm Bioscience did not report revenues by quarter until the third quarter of 2003.

 

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.